Navigation Links
Hospira Expands Board of Directors

LAKE FOREST, Ill., May 13 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), a global specialty pharmaceutical and medication delivery company, announced today that Barbara L. Bowles, CFA, has been elected to the company's board of directors. Bowles brings strong investment management and finance expertise from leadership positions held at major multinational consumer goods companies and equity investment advisory firms. The addition of Bowles expands Hospira's board to nine directors, of whom eight are independent.

"Barbara will be an extraordinary addition to the Hospira board," said Christopher B. Begley, chairman and chief executive officer. "Her broad and deep financial knowledge and corporate policy experience will enhance our current board membership and will be extremely helpful in furthering Hospira's longer-term growth goals."

Bowles, 60, recently retired as vice chair of Profit Investment Management, an investment management firm. Previously, she served as chairman, chief executive officer and chief investment officer of The Kenwood Group, Inc. -- an equity investment advisory corporation that she founded in 1989 -- which was acquired by Profit in January 2006. From 1984 to 1989 she served as corporate vice president of Kraft, Inc., and headed its investor relations department. Earlier in her career, Bowles held equity analyst and trust investment management positions at First National Bank of Chicago (now Chase Bank).

Bowles serves as a director of Black & Decker Corporation, Wisconsin Energy Corporation, Children's Memorial Hospital (Chicago), the Chicago Urban League and Hyde Park Bank. She also is a trustee of Fisk University and the Museum of Science and Industry (Chicago), and serves on the University of Chicago Graduate School of Business Advisory Council. In 2003, she was honored with the "Distinguished Alumni Award" from the African American MBA Association of the University of Chicago.

Bowles is currently pursuing her long-time goal of establishing and funding the Landers-Bowles Family Foundation, which will be primarily focused on charity related to education.

A native of Nashville, Tenn., Bowles holds a master's of business administration degree in finance from the University of Chicago Graduate School of Business, and a bachelor's degree in mathematics, with honors, from Fisk University. She has been a Chartered Financial Analyst (CFA) since 1977.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has more than 14,000 employees. Learn more at

SOURCE Hospira, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Biogenerics Will Save Billions, Says Hospira CEO
2. Hospiras Biosimilar Epoetin Retacrit(TM) Receives Positive Opinion Recommending EU Approval
3. ATS Medical Expands Open Pivot Heart Valve Offerings
4. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
5. BioLife Solutions Expands Scientific Advisory Board
6. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
7. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
8. Pharsight Expands Strategic Consulting Services Team
9. Validus Pharmaceuticals Expands Product Portfolio with Acquisition of Bipolar Drug: Equetro(R)
10. Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing
11. AQUISS Expands Into Significant New Territory
Post Your Comments:
(Date:11/30/2015)... Epigenetics Corp. ("Zenith" or the "Company") today announced that it ... Board of Directors to replace Dr. Peter Johann . ... as co-founder of Resverlogix, with expertise in the fields of ... --> Dr. Wong remarked, "I am very excited to ... expertise in epigenetics and the advanced stage of the R&D ...
(Date:11/30/2015)... ... November 30, 2015 , ... Imagine Exhibitions and Universal Partnerships ... opening in March 2016 at Melbourne Museum in Melbourne, Australia. Immediately following the ... American tour dates. The Exhibition is based on Universal Pictures’ Jurassic World, one ...
(Date:11/30/2015)... 2015 Human Longevity, Inc. (HLI), the genomics-based, ... Cypher Genomics, Inc., a leading genome informatics company offering ... solutions. The San Diego -based company ... CEO and Co-founder, Ashley Van Zeeland , Ph.D., who ... details of the deal were not disclosed. ...
(Date:11/30/2015)... , Nov. 30, 2015  HUYA Bioscience International, ... China,s pharmaceutical innovations, today announced it has ... Development Fund (KDDF) to foster collaboration between KDDF and ... and commercialization of healthcare products for the global market. ... an important source of new innovative preclinical and clinical ...
Breaking Biology Technology:
(Date:11/12/2015)...  Arxspan has entered into an agreement with ... use of its ArxLab cloud-based suite of biological ... will support the institute,s efforts to electronically manage ... internally and with external collaborators. The ArxLab suite ... Institute,s electronic laboratory notebook, compound and assay registration, ...
(Date:11/10/2015)... 2015 About signature verification ... to identify and verify the identity of an ... the secure and accurate method of authentication and ... individual because each individual,s signature is highly unique. ... dynamic signature of an individual is compared and ...
(Date:11/2/2015)...  SRI International has been awarded a contract of ... to the National Cancer Institute (NCI) PREVENT Cancer Program ... modern testing and support facilities, and analytical instrumentation to ... studies to evaluate potential cancer prevention drugs. ... Drug Development Program is an NCI-supported pipeline to bring ...
Breaking Biology News(10 mins):